ERBB2 and breast cancer: After Trastuzumab therapy, HER2 + BC cells that overexpress HIF-1α become the major increased subpopulation, which indicates that cells with higher levels of HIF-1α could survive better under Trastuzumab by upregulating CD73 and CXCR4 expression levels [216–218].